Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716660 | 1.00 | CNR1 (0.44) | CNR1DRD2DRD4DRD3PGR | |
| SCHEMBL15830635 | 0.76 | DRD2 (0.50) | CNR1DRD2DRD4DRD3KDM2B | |
| SCHEMBL3875010 | 0.74 | ALOX5AP (0.45) | — | |
| SCHEMBL427009 | 0.73 | HRH3 (0.42) | MTORKCNH2 | |
| SCHEMBL15824627 | 0.71 | MAPK14 (0.46) | DRD2DRD4DRD3KDM2BPRKDC | |
| SCHEMBL3478611 | 0.71 | KDM2B (0.54) | DRD2DRD4DRD3KDM2BMAPK14 | |
| SCHEMBL22614335 | 0.70 | KDM1A (0.35) | DRD2DRD4DRD3CYP11B1CYP11B2 | |
| SCHEMBL21428775 | 0.70 | MAPK14 (0.42) | PGREGFRPIK3CDABL1HCK | |
| SCHEMBL427101 | 0.70 | FAAH (0.61) | KMOGRIN2BMAPK14 | |
| SCHEMBL21759157 | 0.70 | TGFBR1 (0.45) | CNR1DRD2DRD4DRD3KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936496-B | Heterocyclic compounds useful as medicaments | 马萨里克大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MASARYKOVA UNIVERZITA (CZ) | 2022-11-15 | — | — | US | disclosed |
| EP-3774795-B1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | UNIV MASARYKOVA (CZ) | 2022-03-16 | — | — | EP | disclosed |
| EP-3774795-B1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | UNIV MASARYKOVA (CZ) | 2022-03-16 | — | — | EP | disclosed |
| EP-3774795-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | Masarykova Univerzita (CZ) | 2021-02-17 | — | — | EP | disclosed |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2021-02-11 | — | — | US | disclosed |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2021-02-11 | — | — | US | disclosed |
| CN-111936496-A | Use of 4- (1H-imidazol-5-yl) -1H-pyrrolo [2,3-B ] pyridine for the treatment of leukemias, lymphomas and solid tumors | 马萨里克大学 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019185631-A1 | 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019185631-A1 | 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MALT1, BCL3, MCL1 | CNR1 3081/4885DRD2 4340/4885DRD4 4079/4885 |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MALT1, BCL3, MCL1 | CNR1 3081/4885DRD2 4340/4885DRD4 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.